GLP-1 receptor agonist therapy initiated soon after valve implantation was linked to better survival and fewer complications in people with type 2 diabetes. A study published in the European Heart Journal – Quality of Care and Clinical Outcomes examined post-TAVI outcomes in diabetic patients treated with GLP-1 RAs.

The analysis included 25,184 adults who underwent transcatheter aortic valve implantation between 2015 and 2023. After propensity-score matching,1,101 patients per group were analyzed, with a mean age of 73 years and 39% women. Over a mean follow-up of about 2.4 years, GLP-1 RA therapy was associated with higher survival (hazard ratio 0.71, 95% CI 0.58–0.86) and lower rates of all-cause hospitalization (HR 0.79, 95% CI 0.71–0.89). The therapy also reduced major cardiovascular events (HR 0.85), heart failure exacerbation (HR 0.79), major kidney injury (HR 0.84), and major kidney events (HR 0.67).

These results suggest that GLP-1 RA therapy may protect both the heart and kidneys after TAVI by improving metabolic control and reducing hemodynamic stress. The observational design, lack of adherence data, and high comorbidity burden warrant confirmation through prospective trials.